New Drug Approvals

SEPTEMBER 13, 2024

2] As of July 2022, it is in phase 3 clinical trials for major depressive disorder. [2] 2] Like other kappa opioid antagonists currently under clinical investigation for the treatment of major depression, its efficacy may be compromised by the countervailing activation of pro-inflammatory cytokines in microglia within the CNS. [7]

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Metabolite Tales Blog

JULY 5, 2023

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. With metabolic stability in mind, we take a look at the metabolism of some FDA approved synthetic macrocyclic drugs, and a few of those that were/are in clinical development where metabolism data was available.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. With metabolic stability in mind, we take a look at the metabolism of some FDA approved synthetic macrocyclic drugs, and a few of those that were/are in clinical development where metabolism data was available.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

New Drug Approvals

APRIL 21, 2025

2013 Jun 11;110(24):9992-7. Epub 2013 May 28 PATENT [link] Chemical Synthesis Methyl 3-(3-bromopropoxy)-4-fluorobenzoate (Compound 2) To a solution of methyl 4-fluoro-3-hydroxybenzoate 1 (3.0 No other treatment has demonstrated this degree of treatment effect this quickly in participants with ATTR-CM. [15] 1300761110.

FDA Approval 62

FDA Approval FDA Production Treatment 62